Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed recurrent high grade serous ovarian cancer or triple negative breast cancer~* Subjects with recurrent, metastatic triple negative breast cancer must have had at least 1 chemotherapy regimen for metastatic breast cancer or have developed metastatic breast cancer within 1 year of completion of adjuvant chemotherapy~* Prior therapy for high grade serous ovarian cancer subjects must have included a first-line platinum-based regimen~* At least 4 weeks since prior radiation therapy, 3 weeks since prior chemotherapy and 6 weeks if the last regimen included BCNU or mitomycin C~* At least 4 weeks since any small-molecular kinase inhibitors or any other type of investigational agent~* Life expectancy of at least 4 months~* Able to swallow and tolerate oral medications~Exclusion Criteria:~* Evidence of bowel obstruction, abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of study entry~* Current dependency on IV hydration or total parental nutrition~* Diabetes mellitus unless well controlled~* Pregnant or breast feeding~* History of grade 3 or 4 toxicities with previous PI3kinase inhibitor or PARP inhibitor~* Current or active dermatologic diagnoses that would preclude interpretation of skin toxicities of BKM120~* Receiving any medications or substances that are strong inhibitors or inducers of CYP3A4~* History of cardiac dysfunction or disease~* Persistent toxicities (greater than or equal to CTCAE grade 2) caused by previous cancer therapy~* Major surgery within 14 days of starting study treatment~* Evidence of coagulopathy or bleeding diathesis~* History of major depressive episode, bipolar disorder, obsessive/compulsive disorder, schizophrenia, history of suicide attempt or ideation or homicide/homicidal ideation~* CTCAE grade 3 or greater anxiety~* Uncontrolled, intercurrent illness~* Known HIV positive and on combination antiretroviral therapy~* Receiving chronic treatment with steroids or another immunosuppressive agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm BKM (Type: EXPERIMENTAL): BKM120 and Olaparib
- Arm BYL (Type: EXPERIMENTAL): BYL719 and Olaparib

Based on this trial design, predict the completion outcome and termination type (if applicable).